Global Legal Chronicle: Jacobio’s Pharmaceuticals Group’s Hong Kong IPO

January 22, 2021

O’Melveny advised Jacobio Pharmaceuticals Group Co. on its Hong Kong IPO, including providing guidance on both Hong Kong and United States laws and acting as the chief drafter of the prospectus. Beijing-based Jacobio is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology and other therapies, Global Legal Chronicle reported.

The O’Melveny team was led by partners Ke Geng and Ke Zhu, and included counsel Yiming Liu, Wendy Kan, and Wei Liu, and associates Xiaoyu Xu, Yiying Wang, Henry Wong, and Qianru Hong.

Read the full article here.